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Background/aim: While C-reactive protein (CRP) is a well-studied marker for predicting treatment response and mortality in sepsis,
it was aimed to assess the efficacy of the neutrophil lymphocyte ratio (NLR) as a predictor of mortality and treatment response in sepsis
patients in the intensive care unit (ICU).
Materials and methods: In this retrospective cross-sectional study, sepsis patients were divided according to the presence of septic shock
on the 1st day of ICU stay, and then subgrouped according to mortality. Patient demographics, acute physiologic and chronic health
evaluation II and sequential organ failure assessment scores, NLR and CRP (on the 1st, 3rd, and last day in the ICU), microbiology data,
antibiotic responses, ICU data, and mortality were recorded. Receiver operating characteristic (ROC) curves for the area under curve
(AUC) were calculated for the inflammatory markers and ICU severity scores for mortality.
Results: Of the 591 (65% male) enrolled patients, 111 (18.8%) were nonsurvivors with shock, 117 (19.8%) were survivors with shock,
330 (55.8%) were survivors without shock, and 33 (5.6%) were nonsurvivors without shock. On the 1st day of ICU stay, the NLR and
CRP were similar in all of the groups. On the 3rd day of antibiotic response, the NLR was increased (11.8) in the nonresponsive patients
when compared with the partially responsive (11.0) and responsive (8.5) patients. If the NLR was ≥15 on the 3rd day, the mortality odds
ratio was 6.96 (CI: 1.4–34.1, P < 0.017). The NLR and CRP on the 1st, 3rd, and last day of ICU stay (0.52, 0.58, 0.78 and 0.56, 0.70, 0.78,
respectively) showed a similar increasing trend for mortality.
Conclusion: The NLR can predict mortality and antibiotic responsiveness in ICU patients with sepsis and septic shock. If the NLR
is >15 on the 3rd day of postantibiotic initiation, the risk of mortality is high and treatment should be reviewed carefully.
Key words: Septic shock, intensive care unit, respiratory failure, neutrophil to lymphocyte ratio

1. Introduction
Early recognition of sepsis can lead to early treatment
and a potential reduction in septic shock development
[1]. Despite treatment improvements with the global
sepsis campaign, patients with septic shock have a high
mortality rate in the intensive care unit (ICU) [2–4].
Acute physiological and chronic health evaluation
II (APACHE) and sequential organ failure assessment
(SOFA) scores are well known mortality predictors in
ICU patients with sepsis [5,6]. C-reactive protein (CRP)
and procalcitonin are the most studied inflammatory

markers of bacterial sepsis, particularly for making
decisions regarding antibiotic treatment in the ICU
[7–11]. SOFA and APACHE II scores are calculated to
assess disease severity, treatment response, and risk of
mortality in the ICU, and these are not easy to calculate
at the bed side in daily practice.
There are some inflammatory markers, such as the
neutrophil to lymphocyte ratio (NLR) and platelet
to lymphocyte ratio (PLR), that are used to assess
treatment response in sepsis patients for their simplicity
[12,13].
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Procalcitonin and CRP are the most used biomarkers
to discriminate bacterial sepsis from other inflammatory
diseases [14]. However, CRP can increase in both
infectious and noninfectious diseases and, even though
procalcitonin has a well-defined role as a sepsis biomarker,
it has inconsistent and variable results for the diagnosis
of infectious sepsis, not to mention it is expensive to
assess [15,16]. Recently, studies have been undertaken
on inflammatory markers obtained from complete
blood counts (CBCs) with simple calculations for early
recognition of infection and assessing treatment response
[17–22]. Inflammatory markers obtained by CBCs, such
as the NLR, PLR, platelet to mean platelet volume (MPV),
have been assessed in different disease groups for their
association with hospital mortality [12,13,22,23]. The
NLR has been recommended as an infection biomarker
since 2001 [24] and there have since been studies
evaluating NLR alone, or as part of a multiple biomarker
model, for the diagnosis of adult patients with suspected
community onset sepsis [25,26]. High NLR combined with
lymphocytopenia may be a better predictor of bacteremia
than other routinely used parameters in the emergency
department, such as CRP and the leucocyte count [26]. In
addition, higher NLR and lymphocytopenia values were
correlated with disease severity [24].
It was aimed herein to determine whether NLR obtained from CBCs and with simple calculation can be used
to predict mortality and treatment response in patients
with sepsis and septic shock in the ICU.
2. Materials and methods
This study was performed in a level 3 ICU, in a chest
diseases and thoracic surgery training and research
hospital after approval from the hospital’s local ethics
committee, as prescribed by the Helsinki Declaration.
Due to the retrospective nature of the study, no informed
consent was obtained from the patients.
The ICU was operated by the same intensivist/
pulmonologist team over a 7-day period and each ICU
team followed the same ICU procedures, as defined by
written protocols (such as sepsis, mechanical ventilation,
weaning, etc.).
2.1. Patients
This was designed as a retrospective, observational, and
cross-sectional study, from January 2013 to April 2015.
Patient data, including inclusion and exclusion criteria,
the presence of septic shock on admission to the ICU,
ICU mortality, and assignment according to the presence
of septic shock, are summarized in a flow chart in Figure
1. Patients admitted to the ICU had pulmonary sepsis
and septic shock that was either community acquired
pneumonia or acute exacerbation of chronic obstructive

pulmonary disease. Patients were stratified according to
ICU mortality; categorized as early death (day 1 to 4), or
late death (day 5 or after) [27].
Study endpoint: ICU mortality and discharge from
ICU in patients with septic shock and sepsis alone.
2.2. Definitions
2.2.1. Systemic inflammatory response syndrome (SIRS)
and sepsis-septic shock
Definitions used in the Surviving Sepsis Campaign; an
International Guideline for the Management of Severe
Sepsis and Septic Shock (2012), were deemed valid for the
study period. SIRS is defined by the following criteria: a
pulse rate of 90/min and above or 2 standard deviations
above the normal value for age; a respiratory rate of 20
and above or a partial carbon dioxide pressure (PaCO2) of
32 mmHg and below; alteration of consciousness; a white
blood cell (WBC) count greater than 12,000 µL–1 or below
4000 µL–1; a temperature less than 36 °C or greater than
38.3 °C; plasma glucose levels of >40 mg/dL; a plasma CRP
level 2 standard deviations above the normal value; and
an inspired oxygen fraction of the partial arterial oxygen
concentration (PaO2/FiO2) of <300.
Patients with 2 or more SIRS criteria and with a
suspected or proven infection were defined as having
sepsis [28]. Sepsis induced hypotension was defined as a
systolic arterial pressure of £90 mmHg, a mean arterial
pressure of £65 mmHg, or a decrease in systolic arterial
pressure of >40 mmHg in patients with no other health
issues causing hypotension. As a vasopressor, noradrenalin
was initiated at 0.01–3 µg/kg/min intravenous infusion,
and if necessary, dopamine was added at 5–20 µg/kg/min.
2.3. Recording data
Patient demographics (age, sex, body mass index (BMI)
[kg/m2]), arterial blood gas (ABG) values (Rapidlab, Bayer,
Leverkusen, Germany), and the presence of comorbidities,
such as chronic obstructive pulmonary disease (COPD)
[29], hypertension [30], diabetes mellitus [31], lung cancer,
coronary artery disease, atrial fibrillation, arrhythmia,
Alzheimer’s disease, chronic renal failure, and obesity
hypoventilation syndrome, were recorded on admission
and discharge from the ICU. CBC values, including the
WBC, hematocrit (Htc), platelet, MPV, neutrophil count,
lymphocyte count on the 1st, 3rd, and last day of ICU stay,
calculated NLR, and CRP on the 1st, 3rd, and last day of
ICU stay, were also recorded. In addition, biochemical
values on ICU admission and discharge were recorded.
The APACHE II score was recorded on the day of ICU
admission, and the SOFA score was recorded on the day
of admission and 3rd day in the ICU. The use of invasive
mechanical ventilation (IMV) and noninvasive mechanical
ventilation (NIMV) was noted. Culture results, duration of
ICU stay in days, and ICU mortality were also recorded.

1337

SARI et al. / Turk J Med Sci
ICU patients with sepsis in January 2013-December 2014 n= 770
Inclusion criteria:
Patients who admitted to ICU with sepsis
Age >18
With/without neutropenia

Exclusion criteria:
End stage malignancy
Patients under the age of 18
Patients who developed shock after 24 h of ICU admission

Enrolled Sepsis Patients, n=591
Patients were divided into two groups according to the first 24 h «shock» development
ICU Severity Scores:
SOFA (first-third day of ICU)
APACHE II ( first day of ICU)
Inflammatory Markers:
NRL, CRP,
(first-third and last day of ICU)
Emprical Antibiotic response
Responsive, intermediate, nonresponsive

Sepsis with shock
n=228, 39%

Sepsis without shock
n=363, 61%

Groups were stratified to subgroups according to the ICU mortality

Mortality (+)
Septic shock (+)
n=111, 18.8%

Mortality (-)
Septic shock (+)
n=117, 19.8%

Mortality (+)
Septic shock (-)
n=33, 5.6%

Mortality (-)
Septic shock (-)
n=330, 55.8%

Figure 1. Patient flow chart.

2.4. Calculations
The NLR was calculated as the neutrophil absolute value
over the lymphocyte absolute value. According to the
literature, the patients were grouped according to whether
their NLR values were above or below 10 and 15 on the 1st,
3rd, and last day of ICU stay [32].
2.5. Mechanical ventilation application
In the ICU, all patients not absolutely contraindicated
were initially given NIMV. Contraindications included:
1) heart and/or pulmonary arrest, 2) unconsciousness
(excluding hypercarbia), 3) nonrespiratory organ failure,
severe encephalopathy, shock, heart pathology leading to
unstable hemodynamics, or severe upper gastrointestinal
tract bleeding, 4) lack of airway protection, 5) inability to
remove secretions, 6) risk of aspiration, 7) upper airway
obstruction, and 8) facial surgery, trauma, deformity, or
burning [33]. NIMV failure was defined as the continuation
of acidosis in ABG after NIMV application, aggravation
of respiratory distress, mask and NIMV incompatibility,
hemodynamic instability, cardiac arrest, respiratory
failure, and a loss of consciousness [34]. Patients with
NIMV failure, or in cases where NIMV application
was contraindicated, received IMV via endotracheal
intubation. IMV was defined as volume- or pressurecontrolled, assisted control ventilation, performed based
on the 6–8 mL/kg tidal volume for ideal body weight, or a
plateau pressure equal to or less than 30 cmH2O. For COPD
patients, FiO2 was titrated to 88%–92% oxygen saturation,

1338

and for cardiac ischemic patients, it was titrated to 95%
and above. Positive end expiratory pressure (PEEP) was
titrated, taking into account hemodynamic parameters
in patients with COPD, to 5–6 cmH2O, together with the
mean arterial pressure (65 mmHg and above) and plateau
pressure (30 cmH2O and below). Patients undergoing IMV
were followed up with a fentanyl/midazolam/propofol
infusion as sedation and pain palliation was assessed using
the Richmond agitation and sedation scale [35]. Sedation
was interrupted daily and the patients’ clinical condition
was assessed.
2.6. Weaning protocol
For those patients with improved clinical and laboratory
values, mechanical ventilation support was reduced
and a spontaneous breathing trial was performed. The
spontaneous breathing trial was performed once per day
using a 30-min T-tube test or pressure support ventilation
with a PEEP of 5 cmH20 and pressure support of 8 cmH2O
[36].
2.7. Microbiology
Deep tracheal aspirations were cultured for intubated
patients. Sputum cultures were obtained for nonintubated
patients. In patients with a temperature of <36 °C or >38
°C, blood cultures were taken for aerobes and anaerobes.
In the study period, blood cultures were not taken from
patients with normothermia, as per the hospital infectious
committee protocol for ICU sepsis.
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2.8. Antibiotic response
· Responsive: A sensitive culture response or significant
improvement in the clinical and laboratory values to
treatment showed no culture or a nonreproductive culture
response.
· Partially responsive: Treatment with a moderately
sensitive culture response or partial improvement in
the clinical and laboratory values, in that patients had a
noncultured or nonreproductive culture response.
· Nonresponsive: Treatment with a resistant culture
response or significant deterioration in the clinical and
laboratory values, in that patients had a noncultured or
nonreproductive culture response.
2.9. Statistical analysis
Study data were analyzed using the SPSS v.20.0 (IBM
Corp., Armonk, NY, USA) portable package program. The
continuous numerical values of the binary groups were
compared using Student’s t-test for uniform distribution
and expressed as the mean ± standard deviation.
Nonuniform distribution was assessed using the Mann–
Whitney U test and median quarter-to-quarter ratio.
Dichotomous values were summarized using the chi-square
test. Comparisons of 2 or more groups were compared
using the Kruskal–Wallis test for unevenly distributed
data. Assessment of mortality markers was shown using
the receiver operating characteristic (ROC) curve and
the area under the curve (AUC). Multilogistic regression
analysis was performed using known mortality markers
affecting mortality in the ICU (APACHE II and SOFA
scores), inflammatory markers (CRP, NLR), demographic
characteristics affecting mortality, such as age, male sex,
BMI, and comorbidities found to be significant in binary
variants (heart failure, IMV, antibiotic sensitivity response,
shock upon ICU admission, and length of ICU stay). P <
0.05 was considered statistically significant.
3. Results
Distribution of the study patients into the defined groups
is summarized in Figure 1. During the study period, 591
of 770 patients were included in the study (381 [65%] were
male). The median age was 67 (19–99) years old. Septic
shock within the first 24 h was seen in 39%, and ICU
mortality occurred in 144 (24.4%) of the 591 patients.
The demographic characteristics of the patients relative
to the presence of septic shock are shown in Table 1. Patients
with septic shock were found to have a significantly higher
APACHE II score on ICU admission; they were older and
had more cardiac arrhythmias than those without septic
shock (Table 1). The inflammatory markers and antibiotic
responses are summarized in Table 1.
Patient NLR and CRP values relative to antibiotic
responsiveness over the duration of the ICU stay are
summarized in Table 2. The NLR and CRP values on the

3rd day in the ICU were significantly higher in patients
with partial resistance and resistance to antibiotics,
compared to the antibiotic-sensitive group. Following
treatment, CRP values were similar between the groups on
the last day of ICU stay, but the NLR was statistically lower
in the antibiotic-sensitive group (Table 2).
Table 3 summarizes the ICU data and inflammatory
markers of those patients with pulmonary sepsis relative
to mortality in the ICU within 5 days. Age and sex were
similar in both the survivors and nonsurvivors within 5
days. Apart from lung cancer and COPD, comorbid diseases
were similar whether the patients died within 5 days or
not. A significantly higher rate of nonresponsiveness to
antibiotic treatment, IMV application, and the presence of
septic shock were found in those patients who died within
5 days. Among the inflammatory markers, only the NLR
was significantly higher on the 1st day of ICU stay in those
patients who died within 5 days.
Table 4 shows a comparison of the pulmonary sepsis
patients; demographics, ICU data, and inflammatory
markers of survivors versus nonsurvivors. Older age, a
higher level of inflammatory markers, and a higher rate
of nonresponsiveness to antibiotherapy were found in the
nonsurvivors when compared with the survivors.
Table 5 shows a comparison of the patient APACHE II
and SOFA scores, NLR, and CRP in patients with or without
the occurrence of septic shock and mortality. APACHE II
scores on ICU admission were significantly higher in those
patients who died in the ICU, independent of septic shock.
APACHE II values were similar between those patients
who were in septic shock and those that died in the ICU.
Patients without septic shock had similar SOFA scores on
ICU admission, regardless of their mortality in the followup period. There was a significant difference between all
of the other patient groups. The NLR on ICU admission
was significantly higher in those patients with septic
shock and those who died in the ICU, when compared
with patients without septic shock and survivors. On the
3rd day in the ICU, the SOFA scores were statistically
different in the 4 subgroups. In the subgroup of survivors
with no septic shock, the CRP values on the 3rd day in
the ICU were significantly lower than in the other groups,
and their NLR values were significantly lower than in the
septic shock patients, independent of mortality. The CRP
values of the survivors on the last day of ICU stay were
statistically similar, regardless of the presence of septic
shock, but these values were significantly different in the
nonsurvivor subgroups. The NLR values on the last day
of ICU stay were significantly higher in the nonsurvivors,
independent of the presence of septic shock (Table 5).
Potential mortality risk factors assessed in the
pulmonary sepsis patients during their ICU stay using
binary logistic regression are summarized in Table 6.
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Table 1. A comparison of sepsis patient demographics, ICU data, and inflammatory markers relative to the presence of
septic shock.
Septic shock on admission to the intensive care unit
Absent, n = 392

Present, n = 199

Variable

n

Median (IQR)

n

Median (IQR)

P-value

Age

392

65 (56–75)

199

71 (62–79)

<0.001

Sex, Male n (%)

363

248 (63)

228

133 (67)

0.39

BMI, kg/m

361

23 (21–28)

183

23 (20–28)

0.36

2

Comorbid diseases
Diabetes mellitus

91

23%

51

26%

0.51

Chronic obstructive pulmonary disease

196

50%

95

48%

0.58

Hypertension

158

40%

84

42%

0.67

Coronary arterial disease

49

13%

31

16%

0.30

Atrial fibrillation

38

10%

28

14%

0.11

Cerebrovascular disease

27

7%

20

10%

0.17

Lung cancer

37

9%

29

15%

0.06

5%

14

7%

0.41

3%

9

5%

0.36

6%

7

4%

0.17

Extra-pulmonary cancer
Chronic kidney disease
Obesity hypoventilation syndrome

21
12
24

ICU data
APACHE II score on admission

388

18 (15–23)

197

29 (23–33)

0.001

SOFA score on admission

361

3 (2–4)

228

7 (5–9)

0.001

SOFA score on the 3rd day of ICU stay

325

2 (2–3)

202

5 (3–8)

0.001

Invasive mechanical ventilation,

94

26%

42

18%

0.001

Noninvasive mechanical ventilation,

257

71%

130

57%

0.001

Noninvasive ventilation failure,

32

9%

54

24%

0.001

Length of ICU stay, days

392

6 (4–9)

199

7 (4–12)

0.14

Invasive mechanical ventilation duration, days 120

3 (2–6)

160

4 (2–8)

0.02

Antibiotic responsiveness
Responsive

211

58%

69

30%

Intermediate

130

36%

123

54%

Nonresponsive

22

6%

36

16%

1st day of ICU stay

292

90 (33–160)

174

98 (44–182)

0.13

3rd day of ICU stay

263

73 (2135)

167

125 (62–182)

0.001

Last day of ICU stay

304

43 (20–198)

182

82 (42–155)

0.001

1st day of ICU stay

363

10.50 (5.76–19.56)

228

13.48 (7.54–23.48)

0.001

3rd day of ICU stay

326

8.64 (5.23–15.33)

199

10.97 (6.73–18.41)

0.002

Last day of ICU stay

356

5.93 (3.93–10.25)

220

8.19 (4.47–16.39)

0.001

0.001

CRP, mg/L

NLR

IQR: interquartile range. APACHE II: acute physiologic and chronic health evaluation II. SOFA: sequential organ failure
assessment, NLR: neutrophil to lymphocyte ratio, CRP: C-reactive protein.
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Table 2. Comparison of the NLR and CRP values in response to antibiotic therapy in septic shock patients in the ICU.
Responsive to
Partially responsive to
antibiotherapy
antibiotherapy
Values, median
Values, median
Inflammatory markers n = 280
n = 253
(IQR)
(IQR)
CRP, mg/L

Nonresponsive to
antibiotherapy
values, median
n = 58
P-value
(IQR)

1st day of ICU stay

213

99 (38–175)

204

90 (36–157)

49

95 (43–182)

0.86

3rd day of ICU stay

201

79 (27–140)

190

105 (42–167)

39

115 (84–180)

0.005

Last day of ICU stayv

245

51 (22–108)

199

62 (24–139)

42

74 (20–121)

0.35

1st day of ICU stay

280

11.2 (6.6–17.9)

253

12.7 (6.2–25.1)

58

10.0 (5.4–20.7)

0.17

3rd day of ICU stay

256

8.5 (5.5–14.1)

220

11.0 (6.2–18.0)

49

11.8 (6.5–21.7)

0.008

Last day of ICU stay

273

5.7 (3.8–9.0)

247

9.7 (4.5–15.9)

56

8.4 (4.2–15.7)

0.001

NLR

IQR: interquartile ratio, nonparametric Kruskal–Wallis test.

NLR values of 10 and 15, CRP of 100 mg/L and above on
admission to the ICU, age and BMI, arrhythmia, shock
on admission, number of days in the ICU, and IMV
application were not found to be risk factors for mortality
in the patient group. However, mortality was shown to
be increased by 35.4 times in patients with resistance to
the empirical antibiotic treatment (Table 6), and 10.3-fold
in patients with partial antibiotic resistance. Mortality
increased 7-fold in patients with NLR values of 15 and
above on the 3rd day of ICU stay. Each value increase in
the APACHE II score on admission to the ICU increased
mortality 1.13-fold. Each value increase in the SOFA score
on the 3rd day of ICU stay increased mortality 1.5-fold,
while each value increase in the SOFA score on the 1st day
of ICU stay decreased mortality 0.3-fold (Table 6).
A ROC analysis to predict ICU mortality based on the
APACHE II scores (on ICU admission), SOFA scores (on
ICU admission and on the 3rd day of ICU stay), and NLR
and CRP values (1st, 3rd and last day of ICU stay) is shown
in Figure 2, and the AUC values are summarized in Table 7.
The AUC values were clinically and statistically significant
for the APACHE II and SOFA scores on admission to the
ICU, the SOFA scores and CRP values on the 3rd day of
ICU stay, and CRP and NLR values on the last day of ICU
stay (Table 7).
4. Discussion
This study showed that CRP was similar in patients with
sepsis and septic shock that developed within the first 24
h following admission to the ICU. Significantly higher
NLR levels were found on ICU admission in patients with
septic shock when compared with those with sepsis alone.
The NLR and CRP values behaved similarly relative to the
patient severity and response to treatment during the ICU
stay and ICU outcome. The CRP and NLR values on the
last day of ICU stay were significant predictors of ICU

mortality. The present study also showed that if treatment
with inappropriate antibiotics was initiated, mortality
increased 35-fold. NLR values equal to or greater than 15
on the 3rd day of ICU stay were associated with a 7-fold
increase in mortality. The NLR and CRP showed similar
changes when monitoring the response to antibiotics.
4.1. ICU mortality predictors: APACHE II and SOFA
scores, NLR, and CRP
Recently, Yu et al. compared different evaluating systems
to predict the prognosis of patients with infections outside
of the ICU. During the first 12 h before clinical worsening,
they reported the AUC for the SOFA score as 0.78, and
0.72 for the APACHE II score [37]. A very recent study by
Jain at al., that investigated the SOFA score/ICU mortality
relationship, similarly determined that the higher the
SOFA score on the 1st, 3rd, and 5th day of ICU stay, the
higher the ICU mortality. However, they also showed that
SOFA scores on the 7th and 9th day were not associated
with mortality [38]. In the present study, the AUC for
SOFA score on the 3rd day was the highest value among
the other severity indices (Figure 2 and Table 7).
Salciccioli et al. assessed NLR values as a risk factor for
mortality in the general ICU. They separated patients into
4 groups based on their NLR values and reported that the
presence of sepsis was not an additional risk for mortality
when compared with nonsepsis patients [39]. In the same
study, 3rd and 4th quarter NLR values were found to be
a risk factor for mortality in general ICU patients. The
mortality risk coefficients for the 3rd quarter (75%, NLR =
8.90–16.21) and 4th quarter (75%–100%, NLR of ≥16.21)
NLR were 1.35 and 1.75, respectively. These were similar
to the NLR values of the nonsurvivor sepsis patients in the
ICU in the current study (Table 4). Riché et al. investigated
the relationship between NLR in patients with septic shock
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Table 3. ICU data and inflammatory markers for patients with pulmonary sepsis relative to mortality in
the ICU within 5 days.
Survivors in 5 days

Nonsurvivors in 5 days P-value

n

Values

n

Values

Age

535

67 (57–77)

56

71 (57–80)

0.19

Sex, Male

347

65%

34

61%

0.54

495

23 (21–28)

22

22 (19–25)

0.017

Diabetes mellitus

130

24%

12

21%

0.63

Hypertension

220

41%

22

39%

0.78

COPD

275

52%

16

29%

0.001

Coronary heart diseases

75

14%

5

9%

0.29

Lung cancer

50

9%

16

29%

0.001

Arrhythmia

135

Body mass index kg/m

2

Comorbid diseases

25%

15

27%

0.80

APACHE II score, 1st day of ICU stay 535

20 (16–27)

55

30 (25–38)

0.001

SOFA score, 1st day of ICU stay

535

4 (2–6)

55

8 (5–10)

0.001

SOFA score, 3rd day of ICU stay

503

3 (2–5)

24

9 (6–10)

0.001

Septic shock

184

34%

44

79%

0.001

Culture study

363

68%

28

50%

0.007

Positive culture

91

25%

12

43%

0.039

Responsive

273

51%

7

13%

Intermediate

221

41%

32

57%

Nonresponsive

41

8%

17

30%

Noninvasive

363

68%

24

43%

0.001

Noninvasive failure

76

14%

10

18%

0.46

Invasive

243

45%

37

66%

0.003

1st day of ICU stay

427

94 (34–165)

39

91 (50–187)

0.48

3rd day of ICU stay

419

94 (36–153)

11

180 (116–288)

0.006

Last day of ICU stay

464

53 (21–111)

22

193 (118–333)

0.001

1st day of ICU stay

535

11.23 (6.19–-20.57) 56

17.47 (9.28–27.12) 0.016

3rd day of ICU stay

501

9.33 (5.67–15.67)

24

17.40 (8.42–33.80) 0.004

Last day of ICU stay

529

6.24 (3.95–11.01)

47

17.74 (9.58–31.97) 0.001

Antibiotic responsiveness
0.001

Mechanical ventilation

CRP, mg/L

NLR

and time of death, i.e. early death (before 5 days) and late
death (5th day and after) during ICU stay [27]. The patient
groups had either abdominal sepsis (n = 130) or extraabdominal sepsis (n = 31), and their NLR median values
on admission to the ICU were similar (9.0 [interquartile
range (IQR) of 4.6–17.9] and 11.5 [IQR of 5.5–18.5],
respectively) [27]. In contrast, in the present study, the
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septic patient populations were of a pulmonary sepsis
origin and the early death patients had significantly higher
NLR values than in the study by Riché et al. (median NLR
17 vs. 5) (Table 5). It was also shown that early nonsurvivor
sepsis patients had a significantly higher rate of septic
shock, and higher inflammatory marker values and ICU
severity scores than sepsis patients without shock.
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Table 4. Comparison of pulmonary sepsis patients; demographics, ICU data and inflammatory markers of
survivors versus nonsurvivors.
Survivors

Nonsurvivors

P-values

Number of patients

447

144

-

Male, %

64.4

64.6

0.97

Age, years

66 (57–75)

74 (60–81)

0.001

23 (21–28)

23 (20–26)

0.07

Hypertension

194 (43.5)

48 (33.3)

0.031

Coronary artery diseases

66 (14.8)

14 (9.7)

0.12

Diabetes mellitus

110 (24.6)

32 (22.2)

0.56

Arrhythmias

102 (22.8)

48 (33.3)

0.012

Chronic obstructive pulmonary diseases

240 (53.8)

51 (35.4)

0.001

Cerebrovascular accident

416 (93.1)

128 (88.9)

0.11

Obesity hypoventilation

30 (6.7)

1 (0.7)

0.005

Chronic renal failure

12 (2.7)

9 (6.7)

0.044

Lung cancer

34 (7.6)

32 (22.2)

0.001

APACHE II on admission to the ICU

19 (16–24)

29 (24–35)

0.001

SOFA score on admission to the ICU

3 (2–5)

7 (5–10)

0.001

SOFA score on the 3rd day of ICU stay

3 (2–4)

6 (4–9)

0.001

ICU length of stay, days

6 (4–9)

5 (3–12)

0.23

Septic shock

117 (26.2)

111 (77.1)

0.001

Noninvasive ventilation, n (%)

304 (68)

83 (57.6)

0.023

Noninvasive ventilation days

4 (2-7)

2 (1-4)

0.001

Noninvasive failure to invasive ventilation, n (%)

45 (10.1)

41 (28.5)

0.001

Invasive ventilation, n (%)

173 (38.7)

107 (74.3)

0.001

Invasive ventilation days

3 (2-6)

7 (5-10)

0.008

· responsive

262 (58.6)

18 (12.5)

· intermediate

164 (36.7)

89 (61.8)

· unresponsive

21 (4.7)

37 (25.7)

Insulin infusion, n (%)

22 (4.9)

19 (13.2)

0.001

Steroid (60 mg/day), n (%)

10 (2.2)

12 (8.3)

0.001

Culture sample, N (%)

294 (65.8)

97 (67.4)

0.73

Positive culture sample, n (%)

62 (21.1)

41 (41.8)

0.001

1st day of ICU stay

89 (29–163)

112 (56–169)

0.029

3rd day of ICU stay

81 (28–145)

126 (91–194)

0.001

Last day of ICU stay

44 (20–92)

136 (81–219)

0.001

1st day of ICU stay

10.36 (5.94–19.56)

14.85 (7.54–26.58)

0.006

3rd day of ICU stay

8.56 (5.25–15.27)

13.02 (8.40–19.90)

0.001

Last day of ICU stay

5.50 (3.69–8.71)

15.74 (8.00–28.33)

0.001

Body mass index kg/m

2

Comorbid diseases, n (%)

ICU data

Sepsis protocol
Empirical antibiotic, n (%)
0.001

Inflammatory markers
CRP, mg/L

NLR
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Table 5. Comparison of the inflammatory markers and ICU severity scores with the presence of mortality and septic shock in pulmonary
sepsis patients in the ICU.
Variables

Shock – mortality –

Shock – mortality +

Shock + mortality -

Shock + mortality +

a

b

c

d

n = 330 Values

n = 33 Values

n = 117 Values

n = 111 Values

P-values

ICU admission

APACHE
II score

SOFA
score

CRP

NLR

327

329

264

330

17 (15–22)

3 (2–4)

86 (3160)

32

32

28

10.1(5.7–18.9) 33

24 (20–27)

3 (3–4)

113 (52–152)

117

117

95

13.6 (8.1–22.2) 117

25 (20–30)

6 (5–8)

91 (27–189)

109

111

79

12.7 (7.9–21.5) 111

30 (26–36)

a vs. b < 0.001
a vs. c < 0.001
a vs. d < 0.001
b vs. c = 0.87
b vs. d < 0.001
c vs. d < 0.001

8 (6–10)

a vs. b = 0.68
a vs. c < 0.001
a vs. d < 0.001
b vs. c < 0.001
b vs. d < 0.001
c vs. d < 0.001

102 (57–176)

a vs. b = 0.99
a vs. c = 0.97
a vs. d = 0.24
b vs. c = 0.99
b vs. d = 0.24
c vs. d = 0.61

a vs. b = 0.86
a vs. c = 0.58
a vs. d = 0.009
15.7 (7.5–26.6)
b vs. c = 0.99
b vs. d = 0.73
c vs. d = 0.38

3rd day of ICU stay

SOFA
score

CRP

NLR

1344

298

242

298

2 (2–3)

70 (24–132)

27

21

8.4 (5.0–15.1) 28

4 (3–5)

112 (80–180)

117

100

12.9 (9.2–17.9) 115

4 (3–6)

119 (54–175)

85

67

10.1 (6.2–15.4) 84

8 (5–10)

a vs. b = 0.000
a vs. c = 0.000
a vs. d = 0.000
b vs. c = 0.91
b vs. d = 0.000
c vs. d = 0.000

135 (97–196)

a vs. b = 0.045
a vs. c = 0.001
a vs. d = 0.000
b vs. c = 0.94
b vs. d = 0.78
c vs. d = 0.09

a vs. b = 0.05
a vs. c = 0.045
a vs. d = 0.000
13.5 (8.3–20.8)
b vs. c = 0.75
b vs. d = 0.99
c vs. d = 0.32
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Table 5. Continued.
Last day of ICU stay

CRP

NLR

282

324

40 (18–92)

5.5 (3.8–8.6)

22

32

103 (51–202)

107

15.1 (8.2–24.5) 117

53 (23–92)

5.4 (2.4–8.7)

a vs. b < 0.001
a vs. c = 0.61
a vs. d < 0.001
b vs. c < 0.001
b vs. d = 0.97
c vs. d < 0.001

75

151 (85–221)

103

a vs. b < 0.001
a vs. c = 0.99
a vs. d <0.001
16.0 (8.0–30.5)
b vs. c < 0.001
b vs. d = 0.31
c vs. d < 0.001

*Non-parametric Kruskal Wallis Test, median values (25%–75%).
Table 6. Mortality risk factors evaluated by binary logistic regression in
pulmonary sepsis patients in the ICU.
Odds ratio

CI 95% lower-upper P-values

Partially responsive

10.3

3.3–31.5

<0.001

Nonresponsive

35.4

7.9–158.3

<0.001

3rd day NLR of ≥15

6.96

1.42–34.1

0.017

3rd day NLR of ≥10

2.71

0.63–11.63

0.18

1st day NLR of ≥15

1.27

0.32–4.92

0.72

1st day NLR of ≥10

0.53

0.14–2.01

0.36

3rd day SOFA score

1.57

1.23–2.01

<0.001

1st day SOFA score

0.69

0.54–0.89

0.005

1st day APACHE II score

1.12

1.03–1.23

0.005

1st day CRP of >100

1.04

0.40–2.68

0.92

3rd day CRP of >100

0.64

0.21–1.97

0.44

Age

0.98

0.94–1.02

0.36

BMI

0.96

0.89–1.03

0.27

IMV

2.38

0.73–7.76

0.15

Arrhythmia

2.48

0.85–7.17

0.09

Shock on admission

2.54

0.92–6.99

0.07

ICU days

1.00

0.94–1.06

0.85

Antibiotic response

CI: confidence interval, BMI: body mass index, IMV: invasive mechanical
ventilation.

4.2. Antibiotic response: CRP, NLR, and procalcitonin
Schmit et al. investigated the clinical course of CRP in
response to initial antibiotic therapy in sepsis patients.
They found CRP to predominantly increase within the first
48 h of treatment, and by at least 2.2 mg/dL [40]. These

findings were similar in patients in the current study who
were partially sensitive or resistant to antibiotics; they
tended to have elevated CRP levels on the 3rd day of ICU
stay. Renny et al. indicated that a drop in CRP of 50 mg/
dL or more from ICU admission to the 4th day of ICU
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Figure 2. Mortality prediction markers in pulmonary sepsis patients in the ICU; ROC curve analysis.

stay was a good cutoff value for anticipating recovery in
sepsis patients [41]. The CRP and NLR values on the 1st
and 3rd day of ICU stay in sepsis patients in the present
study were assessed according to guidelines that suggested
that the response to the initial antibiotic therapy should
be assessed by a regression in biomarkers and clinical
response within the first 48–72 h [42]. While the CRP
and NLR values increased on the 3rd day in the partiallysensitive and antibiotic-resistant patient groups, the
CRP and NLR values decreased on the last day following
treatment modification.
Gürol et al. assessed procalcitonin as a reference and
predictor of sepsis and septic shock and compared it with
the NLR, CRP and leucocyte counts using ROC analysis
[43]. They concluded that the strongest indicator for sepsis
was NLR. If the NLR was equal to 5 or above, it indicated
a sepsis diagnosis, and the requirement for treatment and
follow-up of infection in a critically ill patient. The authors
defined procalcitonin values from 2–10 ng/mL in patients
with sepsis and 10 ng/mL in patients with septic shock.
They also defined values for NLR in the range of 13–15
for patients with sepsis and over 15 for patients with septic
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shock. Unlike their study, in which admission values with
suspected bacteremia were taken into account, patients
in the present study had pulmonary sepsis. Significantly
higher values of NLR and CRP were observed in patients
with sepsis and septic shock in the ICU (Table 1). After
empirical antibiotic therapy, the NLR and CRP were significantly higher on the 3rd day in the nonresponsive sepsis/septic shock patients (Table 2).
4.3. Limitations
A limitation of this study was that it was retrospective
and single-centered. However, given that the center where
the patients’ records were taken from and the study was
done at had a consistent team of ICU physicians who
implemented a specific sepsis protocol, we can say that the
data were controllable, even if acquired retrospectively. We
believe that the results presented herein are significant, as
the number of patients assessed was high and they were
treated and followed by a specific group of physicians.
A further limitation was that the sepsis patients were
of a pulmonary origin and the study was conducted in
the pulmonary ICU. Thus, we could not generalize our
results for other causes of sepsis. Nevertheless, pulmonary
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Table 7. Area under the curve for mortality in pulmonary sepsis patients in the ICU.
Asymptotic 95% confidence interval

Test result variable(s)

Area

P-values

Lower bound

Upper bound

SOFA, 3rd day of ICU stay

0.807

0.001

0.744

0.870

CRP, last day of ICU stay

0.780

0.001

0.712

0.849

NLR, last day of ICU stay

0.778

0.001

0.705

0.851

APACHE II, 1st day of ICU stay 0.740

0.001

0.672

0.809

SOFA, 1st day of ICU stay

0.723

0.001

0.652

0.795

CRP, 3rd day of ICU stay

0.699

0.001

0.632

0.766

NLR, 3rd day of ICU stay

0.579

0.06

0.501

0.658

CRP, 1st day of ICU stay

0.562

0.14

0.487

0.638

NLR, 1st day of ICU stay

0.515

0.73

0.431

0.599

originated sepsis is a frequently occurring type of sepsis
encountered by intensivists in the intensive care [44]. We
believe that our data is valuable for ICU physicians in
clinical practice.
4.4. Conclusions
For patients with sepsis and septic shock, NLR and CRP
values on admission to the ICU (within the first 24 h) are
not as valuable as the 1st day SOFA and APACHE II scores
for predicting mortality. The NLR is as valuable as CRP

for assessing the response to empirically initiated antibiotic treatment in sepsis patients. NLR values of >15 on the
3rd day of ICU stay can be used to predict mortality. We
suggest using NLR values for sepsis patients in the first 3
days to assess follow-up and antibiotic treatment. Further
studies are required to clarify these results and to assess
the utility of NLR as a predictor of mortality and treatment
response in other sepsis and septic shock patient populations.

References
1.

Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM et al.
Definitions for sepsis and organ failure and guidelines for
the use of innovative therapies in sepsis. The ACCP/SCCM
Consensus Conference Committee. American College of Chest
Physicians/Society of Critical Care Medicine. 1992; 101 (6):
1644-55. doi: 10.1378/chest.101.6.1644

6.

Vincent JL, Moreno R, Takala J, Willatts S, De Mendonça A et al.
The SOFA (Sepsis-related Organ Failure Assessment) score to
describe organ dysfunction/failure. On behalf of the Working
Group on Sepsis-Related Problems of the European Society of
Intensive Care Medicine. Intensive Care Medicine 1996; 22 (7):
707-10.

2.

Levy MM, Fink MP, Marshall JC, Abraham E, Angus D et
al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis
Definitions Conference. Critical Care Medicine 2003; 31 (4):
1250-6. doi: 10.1097/01.CCM.0000050454.01978.3B

7.

Henriquez-Camacho C, Losa J. Biomarkers for sepsis.
Biomed Research International 2014; 2014: 547818. doi:
10.1155/2014/547818

3.

Dellinger RP, Carlet JM, Masur H, Gerlach H, Calandra T et
al. Surviving Sepsis Campaign guidelines for management of
severe sepsis and septic shock. Critical Care Medicine 2004; 32
(3): 858-73. doi: 10.1097/01.CCM.0000117317.18092.E4

8.

Pierrakos C, Vincent JL Sepsis biomarkers: a review. Critical
Care 2010; 14 (1): R15. doi: 10.1186/cc8872.

9.

Lichtenstern C, Brenner T, Bardenheuer HJ, Weigand MA.
Predictors of survival in sepsis: what is the best inflammatory
marker to measure? Current Opinion Infectious Diseases 2012;
25 (3): 328-36. doi: 10.1097/QCO.0b013e3283522038.

10.

Jolivet P, Christen G, Seematter G, Que YA, Eggimann P.
Usefulness of biomarkers of sepsis in the ICU. Revue Medicale
Suisse 2011; 7 (321): 2430-4.

11.

Wacker C, Prkno A, Brunkhorst FM, Schlattmann P.
Procalcitonin as a diagnostic marker for sepsis: a systematic
review and meta-analysis. Lancet Infectious Disease. 2013; 13
(5): 426-35. doi: 10.1016/S1473-3099(12)70323-7.

4.

5.

Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H
et al. Surviving sepsis campaign: international guidelines
for management of severe sepsis and septic shock: 2012.
Critical Care Medicine 2013; 41 (2): 580-637. doi: 10.1097/
CCM.0b013e31827e83af.
Knaus WA, Zimmerman JE, Wagner DP, Draper EA, Lawrence
DE. APACHE-acute physiology and chronic health evaluation:
a physiologically based classification system. Critical Care
Medicine 1981; 9 (8): 591-7.

1347

SARI et al. / Turk J Med Sci
12.

Ma Y, Mao Y, He X, Sun Y, Huang S et al. The values of
neutrophil to lymphocyte ratio and platelet to lymphocyte
ratio in predicting 30 day mortality in patients with acute
pulmonary embolism. BMC Cardiovascular Disorders 2016;
16: 123. doi:10.1186/s12872-016-0304-5

23.

Duman D, Aksoy E, Agca MC, Kocak ND, Ozmen I et al.
The utility of inflammatory markers to predict readmissions
and mortality in COPD cases with or without eosinophilia.
International Journal of Chronic Obstructive Pulmonary
Disease 2015; 10: 2469-78. doi: 10.2147/COPD.S90330.

13.

Jagadesham VP, Lagarde SM, Immanuel A, Griffin SM.
Systemic inflammatory markers and outcome in patients
with locally advanced adenocarcinoma of the oesophagus and
gastro-oesophageal junction. British Journal of Surgery 2017;
104: 401-407. doi: 10.1002/bjs.10425

24.

Zahorec R. Ratio of neutrophil to lymphocyte counts rapid
and simple parameter of systemic inflammation and stress in
critically ill. Bratislavske Lekarske Listy 2001; 102 (1): 5-14.

25.

Ljungström L, Pernestig AK, Jacobsson G, Andersson
R, Usener B et al. Diagnostic accuracy of procalcitonin,
neutrophil-lymphocyte count ratio, C-reactive protein, and
lactate in patients with suspected bacterial sepsis. PLoS ONE
12 (7): e0181704. doi: 10.1371/journal.pone.0181704.

26.

de Jager CP, van Wijk PT, Mathoera RB, de Jongh-Leuvenink
J, van der Poll T et al. Lymphocytopenia and neutrophillymphocyte count ratio predict bacteremia better than
conventional infection markers in an emergency care unit.
Critical Care 2010; 14 (5): R192. doi: 10.1186/cc9309.

27.

Anand D, Das S, Bhargava S, Srivastava LM, Garg A et al.
Procalcitonin as a rapid diagnostic biomarker to differentiate
between culture-negative bacterial sepsis and systemic
inflammatory response syndrome: a prospective, observational,
cohort study. Journal of Critical Care 2015; 30 (1): 218.e7-12.
doi: 10.1016/j.jcrc.2014.08.017.

Riché F, Gayat E, Barthélémy R, Le Dorze M, Matéo J et al.
Reversal of neutrophil-to-lymphocyte count ratio in early
versus late death from septic shock. Critical Care 2015; 19: 439.
doi: 10.1186/s13054-015-1144-x.

28.

Arif SK, Sumange Rukka AB, Wahyuni S. Comparison of
neutrophils-lymphocytes ratio and procalcitonin parameters
in sepsis patient treated in intensive care unit Dr. Wahidin
Hospital, Makassar, Indonesia. Journal of Medical Science
2017; 17 (1): 17-21. doi: 10.3923/jms.2017.17.21

See comment in PubMed Commons belowDellinger
RP. Surviving sepsis campaign: international guidelines
for management of severe sepsis and septic shock: 2012.
Critical Care Medicine 2013; 41 (2): 580-637. doi: 10.1097/
CCM.0b013e31827e83af.

29.

Naess A, Nilssen SS, Mo R, Eide GE, Sjursen H. Infection. Role
of neutrophil to lymphocyte and monocyte to lymphocyte
ratios in the diagnosis of bacterial infection in patients with
fever. Infection 2017; 45 (3): 299-307. doi: 10.1007/s15010016-0972-1.

Vestbo J, Hurd SS, Rodriguez-Roisin R. The 2011 revision of the
global strategy for the diagnosis, management and prevention
of COPD (GOLD)--why and what? Clinical Respiratory
Journal 2012; 6 (4): 208-14. doi: 10.1111/crj.12002.

30.

Mancia G. 2007 Guidelines for the Management of Arterial
Hypertension: The Task Force for the Management of Arterial
Hypertension of the European Society of Hypertension (ESH)
and of the European Society of Cardiology (ESC). Journal
of Hypertension 2007; 25 (6): 1105-87. doi: 10.1097/
HJH.0b013e3281fc975a

31.

Garber AJ, Abrahamson MJ, Barzilay JI, Blonde L, Bloomgarden
ZT et al. Consensus statement by the American Association
of Clinical Endocrinologists and American College of
Endocrinology on the comprehensive type 2 diabetes
management algorithm--2015 executive summary. Endocrine
Practice 2015; 21 (12): 1403-14. doi: 10.4158/EP151063.CS.

32.

Saltürk C, Karakurt Z, Adiguzel N, Kargin F, Sari R et al. Does
eosinophilic COPD exacerbation have a better patient outcome
than non-eosinophilic in the intensive care unit? International
Journal of Chronic Obstructive Pulmonary Disease 2015; 10:
1837-46. doi: 10.2147/COPD.S88058

33.

Leger P, Hill N, Criner G. Clinical indications for noninvasive
positive pressure ventilation in chronic respiratory failure
due to restrictive lung disease, COPD, and nocturnal
hypoventilation--a consensus conference report. Chest 1999;
116 (2): 521-34. doi: 10.1378/chest.116.2.521

14.

15.

16.

17.

18.

19.

See comment in PubMed Commons belowRhodes A, Evans
LE, Alhazzani W, Levy MM, Antonelli M et al. Surviving sepsis
campaign: international guidelines for management of sepsis
and septic shock: 2016. Intensive Care Medicine 2017; 43 (3):
304-377. doi: 10.1097/CCM.0000000000002255.
Hoenigl M, Raggam RB, Wagner J, Prueller F, Grisold AJ et
al. Procalcitonin fails to predict bacteremia in SIRS patients:
a cohort study. International Journal of Clinical Practice 2014;
68 (10): 1278-81. doi: 10.1111/ijcp.12474.

Shinde VS, Kakrani VA, Gokhale VS, Thombre SK, Landge
JA. Comparison of neutrophil to lymphocyte count ratio,
APACHE II score and SOFA score as prognostic markers in
the setting of emergency medicine. International Journal of
Healthcare and Biomedical Research 2016; 4 (4): 46-5

20.

Hwang SY ,Shin TG, Jo IJ, Jeon K, Suh GY et al. Neutrophil-tolymphocyte ratio as a prognostic marker in critically-ill septic
patients. American Journal of Emergency Medicine 2017; 35
(2): 234-239. doi: 10.1016/j.ajem.2016.10.055.

21.

Oh GH, Chung SP, Park YS, Hong JH, Lee HS et al. Mean
platelet volume to platelet count ratio as a promising predictor
of early mortality in severe sepsis. Shock. 2017; 47 (3): 323-330.
doi: 10.1097/SHK.0000000000000718.

22.

Yang W, Wang X, Zhang W, Ying H, Xu Y et al. Neutrophillymphocyte ratio and platelet-lymphocyte ratio are 2 new
inflammatory markers associated with pulmonary involvement
and disease activity in patients with dermatomyositis. Clinica
Chimica Acta 2017; 465: 11-16. doi: 10.1016/j.cca.2016.12.007

1348

SARI et al. / Turk J Med Sci
34.

Nava S, Hill N. Non-invasive ventilation in acute respiratory
failure. Lancet 2009; 374 (9685): 250-259. doi: 10.1016/S01406736(09)60496-7.

35.

Sessler CN, Gosnell MS, Grap MJ, Brophy GM, O’Neal PV
et al. The Richmond Agitation-Sedation Scale: validity and
reliability in adult intensive care unit patients. See comment
in PubMed Commons belowAmerican Journal of Respiratory
and Critical Care Medicine 2002; 166 (10): 1338-44. doi:
10.1164/rccm.2107138

36.

Boles JM, Bion J, Connors A, Herridge M, Marsh B et al.
Weaning from mechanical ventilation. See comment in
PubMed Commons belowThe European Respiratory Journal
2007; 29 (5): 1033-56. doi: 10.1183/09031936.00010206

37.

Yu S, Leung S, Heo M, Soto GJ, Shah RT et al. See comment
in PubMed Commons Comparison of risk prediction scoring
systems for ward patients: a retrospective nested case-control
study. Critical Care 2014; 18 (3): R132. doi: 10.1186/cc13947

38.

Jain A, Palta S, Saroa R, Palta A, Sama S et al. Sequential organ
failure assessment scoring and prediction of patient’s outcome
in intensive care unit of a tertiary care hospital. Journal of
Anaesthesiology, Clinical Pharmacology 2016; 32 (3): 364-8.
doi: 10.4103/0970-9185.168165

39.

Salciccioli JD, Marshall DC, Pimentel MA, Santos MD, Pollard
T et al. The association between the neutrophil-to-lymphocyte
ratio and mortality in critical illness: an observational cohort
study. Critical Care 2015; 19: 13. doi: 10.1186/s13054-0140731-6.

40.

Schmit X, Vincent JL. The time course of blood C-reactive
protein concentrations in relation to the response to initial
antimicrobial therapy in patients with sepsis. Infection 2008;
36 (3): 213-9. doi: 10.1007/s15010-007-7077-9.

41.

Reny JL, Vuagnat A, Ract C, Benoit MO, Safar M et al. Diagnosis
and follow-up of infections in intensive care patients: value of
C-reactive protein compared with other clinical and biological
variables. Critical Care Medicine 2002; 30 (3): 529-35.

42.

Friedland HD, O’Neal T, Biek D, Eckburg PB, Rank DR et al.
CANVAS 1 and 2: analysis of clinical response at day 3 in two
phase 3 trials of ceftaroline fosamil versus vancomycin plus
aztreonam in treatment of acute bacterial skin and skin structure
infections. Antimicrobial Agents and Chemotheraphyv2012;
56 (5): 2231–2236. doi: 10.1128/AAC.05738-11

43.

Gürol G, Çiftci İH, Terizi HA, Atasoy AR, Ozbek A et al. Are
there standardized cutoff values for neutrophil-lymphocyte
ratios in bacteremia or sepsis? Journal of Microbiology and
Biotechnology 2015; 25 (4): 521-5. doi: 10.4014/jmb.1408.08060

44.

Calandra T, Cohen J. The international sepsis forum consensus
conference on definitions of infection in the intensive care unit.
Critical Care Medicine 2005; 33 (7): 1538-48. doi: 10.1097/01.
CCM.0000168253.91200.83

1349

